Shares of Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $32.18, but opened at $31.36. Cassava Sciences shares last traded at $26.66, with a volume of 2,590,834 shares trading hands.
Analyst Ratings Changes
A number of research firms have recently issued reports on SAVA. HC Wainwright reaffirmed a "buy" rating and set a $116.00 target price on shares of Cassava Sciences in a report on Friday, November 8th. Rodman & Renshaw reiterated a "buy" rating and issued a $107.00 price objective on shares of Cassava Sciences in a report on Thursday, August 8th.
Read Our Latest Analysis on Cassava Sciences
Cassava Sciences Trading Down 17.7 %
The company has a market capitalization of $1.27 billion, a PE ratio of -19.19 and a beta of -0.59. The company has a fifty day simple moving average of $27.55 and a 200-day simple moving average of $23.38.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.79. During the same quarter in the previous year, the business posted ($0.61) earnings per share. On average, equities analysts predict that Cassava Sciences, Inc. will post -3.63 EPS for the current fiscal year.
Institutional Trading of Cassava Sciences
A number of hedge funds and other institutional investors have recently made changes to their positions in SAVA. Geode Capital Management LLC raised its holdings in Cassava Sciences by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,593 shares of the company's stock valued at $29,688,000 after buying an additional 41,289 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Cassava Sciences during the third quarter valued at about $10,610,000. Vanguard Group Inc. raised its stake in shares of Cassava Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company's stock valued at $47,813,000 after acquiring an additional 31,854 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Cassava Sciences by 18.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 140,847 shares of the company's stock worth $1,739,000 after acquiring an additional 21,558 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Cassava Sciences during the 3rd quarter worth approximately $605,000. Institutional investors and hedge funds own 38.05% of the company's stock.
Cassava Sciences Company Profile
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
See Also
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
